Table 2 Baseline characteristics of study subjects
Parameters | Rheumatoid arthritis patients | Healthy controls |
|---|---|---|
Total numbers | 211 | 303 |
Gender (F/M) | 156/55 | 210/93 |
Age (Mean ± SE) | 42.9 ± 13.5 | 46.1 ± 18.3 |
Disease duration (Months) | 18.3 ± 9.4 | NR |
Swollen joint counts (0–28) | 7.0 | NR |
Tender joint counts (0–28) | 13.0 | NR |
DAS28 score (%) | Â | NR |
 < 3.2 | 30.3 |  |
 Between 3.2–5.1 | 36.9 |  |
 > 5.1 | 32.8 |  |
SJC out of 66 | 9.4 ± 6.3 | NR |
ESR (mm at 1st hour) | 37.6 ± 21.4 | 17.8 ± 11.2 |
CRP (mg/mL) | 18.9 ± 22.4 | 1.19 ± 13.2 |
RF positivity (%) | 63 | NR |
Anti-CCP antibody positive (%) | 62 | NR |
Treatment Details | Â | NR |
 Methotrexate | 52% |  |
 Sulphasalazine | 46% |  |
 Hydroxychloroquine | 5% |  |
 Leflunomide | 2% |  |
 Tocilizumab | 12% |  |
 Adalimumab | 6% |  |
 Infliximab | 5% |  |
 Prednisone | 12% |  |